MAPS Successfully Clears Path for Cannabis Research through FDA Formal Dispute
SAN JOSE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) — The U.S. Food and Drug Administration (FDA) Division of Psychiatry Products has cleared the Multidisciplinary Association for Psychedelic Studies (MAPS
)’ Phase 2 study of smoked cannabis in Veterans for th…
- After three years of negotiation with the FDA, MAPS has successfully secured FDA clearance to conduct a clinical trial, MJP2, to examine the use of smoked cannabis for the treatment of PTSD s…